International corporate finance:
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
Mason, Ohio
Thomson South-Western
2006
|
| Ausgabe: | 8. ed., internat. student ed. |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | Bis 7. Aufl. u.d.T.: Madura, Jeff: International financial management |
| Beschreibung: | XXIII, 707 S. graph. Darst. |
| ISBN: | 0324323824 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV020839694 | ||
| 003 | DE-604 | ||
| 005 | 20080318 | ||
| 007 | t | ||
| 008 | 051020s2006 d||| |||| 00||| eng d | ||
| 020 | |a 0324323824 |9 0-324-32382-4 | ||
| 035 | |a (OCoLC)254145015 | ||
| 035 | |a (DE-599)BVBBV020839694 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-1049 |a DE-1051 |a DE-858 |a DE-83 | ||
| 082 | 0 | |a 658.1599 | |
| 084 | |a QK 640 |0 (DE-625)141673: |2 rvk | ||
| 100 | 1 | |a Madura, Jeff |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a International corporate finance |c Jeff Madura |
| 250 | |a 8. ed., internat. student ed. | ||
| 264 | 1 | |a Mason, Ohio |b Thomson South-Western |c 2006 | |
| 300 | |a XXIII, 707 S. |b graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 500 | |a Bis 7. Aufl. u.d.T.: Madura, Jeff: International financial management | ||
| 650 | 4 | |a Multinationales Unternehmen / Betriebliche Finanzwirtschaft / Währungsmanagement / Welt | |
| 650 | 4 | |a Multinationales Unternehmen | |
| 650 | 4 | |a Foreign exchange | |
| 650 | 4 | |a Foreign exchange |v Problems, exercises, etc | |
| 650 | 4 | |a International business enterprises |x Finance | |
| 650 | 4 | |a International business enterprises |x Finance |v Problems, exercises, etc | |
| 650 | 4 | |a International finance | |
| 650 | 4 | |a International finance |v Problems, exercises, etc | |
| 650 | 0 | 7 | |a Internationaler Kreditmarkt |0 (DE-588)4120506-6 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Finanzmanagement |0 (DE-588)4139075-1 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Finanzmanagement |0 (DE-588)4139075-1 |D s |
| 689 | 0 | 1 | |a Internationaler Kreditmarkt |0 (DE-588)4120506-6 |D s |
| 689 | 0 | |5 DE-604 | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=014161594&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
Datensatz im Suchindex
| _version_ | 1805072702001643520 |
|---|---|
| adam_text |
Contents
List of figures page xi
List of contributors xvi
Preface xix
Acknowledgments xxi
1 The business of healthcare innovation in the Wharton
School curriculum 1
Lawton R. Bums
Part I The life sciences
2 The pharmaceutical sector 27
Jon Northrup
3 The biotechnology sector - therapeutics 103
Cary G. Pfeffer
4 Biotechnology business and revenue models: the dynamic of
technological evolution and capital market ingenuity 190
Stephen M. Sammut
5 Mergers, acquisitions, and the advantages of scale in the
pharmaceutical sector 223
Lawton R. Burns, Sean Nicholson, and John Evans
Part II Devices and information technologies
6 The medical device sector 271
Kurt Kruger
7 The healthcare information technology sector 322
Jeff C. Goldsmith
8 Healthcare innovation across sectors: convergences and divergences 348
Lawton R. Burns and Stephen M. Sammut
Index 365
Figures
1.1 The US healthcare value chain page 2
1.2 Technology and intensity of service as share of
annual percentage increase in US personal health
expenditures, 1961-1998 3
1.3 Composition of hospital expenses 11
1.4 Composition of hospital supply costs 12
1.5 Spending by category, 1980-2010 12
1.6 US healthcare manufacturing firms: revenues and rank
in Fortune 500 14
2.1 2003: heavily about the USA 29
2.2 Growth of key markets 30
2.3 Top worldwide countries (except USA) over \$4 billion
country sales 31
2.4 Sales of top companies, 2003 31
2.5 Twelve largest pharmaceutical companies grow to 2007,
slow to 2010 32
2.6 Therapeutic area growth, 2002-2010 33
2.7 Drug development attrition rate 35
2.8 Individual healthcare status 44
2.9 USA population over 65 years of age 46
2.10 Age profile in major markets, 2010: Brazil, Japan, US 47
2.11 Worldwide prescription consumers - 2010 48
2.12 Worldwide disease potential 52
2.13 Top twenty future diseases in 2010 52
2.14 Three dimensions of pharmaceutical strategy 53
2.15 The value chain 54
2.16 Varying scope of pharmaceutical business models 54
2.17 Stages in the discovery research process 56
2.18 The investment inflection point: addressing early attrition 60
2.19 Stages in the development process 60
2.20 Pharmaceutical business model - long cycle time and
high risk 61
2.21 Personalized medicine: genaissance example 63
2.22 Drug development cost 68
2.23 The innovation challenge 68
2.24 Technology applied to drug development 69
2.25 Key innovation levers are moving in the wrong direction 71
2.26 Drug candidate attrition: pull risk forward 71
2.27 Fast fails: comparison of two companies (early decision
and traditional development) 72
2.28 Pharmaceutical supply chain 74
2.29 Top 5,000 molecules by 2001 revenue 82
2.30 Blockbuster revenue correlates to shareholder returns 82
2.31 Increasing rewards from new launch standards 83
2.32 Spending begins early and aggressively 84
2.33 Total pharmaceutical promotional spend 84
2.34 US sales representatives "arms race" 85
2.35 E-detailing 88
2.36 Cycle times 90
2.37 Lilly's product archetypes 91
2.38 Goal - strong, steady innovation matched to
franchise engines 92
2.39 Pharmaceutical deals between 2002 and 2004 94
2.40 Alliance life cycle - breakdowns are normal 95
2.41 Key element of successful alliance management 96
2.42 It is not the number of shots on goal - data from 2000
NHL season 100
3.1 Discoveries driving the biotechnology industry 106
3.2 The biotechnology industry - year of company founding 108
3.3 Recent stock market performance 109
3.4 US biotechnology companies versus Merck and Pfizer 110
3.5 US biotechnology revenues 111
3.6 Selected biotechnology-derived drugs 112
3.7 Therapeutic monoclonal antibody products approved
in the US 117
3.8 Selected genomics companies 118
3.9 Selected proteomics companies 119
3.10 Selected systems biology companies 123
3.11 Technology platform companies 125
3.12 Selected Millennium pharmaceutical alliances 127
3.13 Selected Millennium acquisitions 128
3.14 Venture funding trends for NRDO companies versus
R D companies 130
3.15 NRDO versus R D company financings
(public and private) 130
3.16 IPOs versus venture capital funding 132
3.17 Financing alternatives 134
3.18 Biotech financing trends, 1996-2003 137
3.19 Biotech financings 1996 and 2003 138
3.20 Comparison of pharmaceutical and biotechnology
companies 140
3.21 What makes alliances work 142
3.22 Licensing deals by phase, 1998-2003 144
3.23 Selected early partial acquisitions in biotechnology 144
3.24 Value of prescription drugs coming off-patent 146
3.25 Selected M A transactions involving biotechnology
companies 149
3.26 Comparing the domestic biotech industry with the
rest of the world 154
3.27 Biotechnology products in development across Europe 155
3.28 UK biotechnology financing 156
3.29 Aggregate market capitalization of biotechnology
companies across Europe 157
3.30 Number of companies by European country 158
3.31 Canadian biotechnology: sources of funding 159
3.32 Number of Asian biotechnology companies
(public and private) by country 161
3.33 Top industries for Japanese venture capital investment 162
3.34 Selected biotechnology products in Japan in 2003 162
3.35 Funding sources for Australian biotechnology firms,
2001-2002 166
3.36 Selected challenges of commercializing drugs in
foreign markets 167
3.37 Federal biotechnology regulatory framework 168
3.38 FDA biologies approval times, 2001-2003 169
3.39 Trend of FDA biologies approval times 170
3.40 New product approvals (NMEs), 1996-2003 170
3.41 Selected top biopharmaceuticals and their biogeneric status 174
3.42 Orphan drug approvals 175
3.43 The pharmaceutical innovation gap 182
4.1 Innovation gap in pharmaceutical discovery and
development 196
4.2 Proteomics toolbox technologies 198
4.3 The "omics" development chain 199
4.4 Specialty participants in the proteomics continuum 201
4.5 Biotechnology industry characteristics in 2004 211
4.6 Capitalization trends in the US life sciences industry 212
4.7 Representation of the dynamics of biotechnology
strategies and structures and their revenue models 215
5.1 Number of "transforming" biotechnology and
pharmaceutical M A transactions 227
5.2 Merger history of top companies, 1979-2004 228
5.3 Alliances with biotechnology firms 230
5.4 Top rationales for recent pharmaceutical merger 250
5.5 An integrating industry 255
6.1 Medical device industry 272
6.2 Medical devices markets - major categories 2003 277
6.3 Cardiovascular product detail - 2003 revenue 278
6.4 A selection of large US medical device companies,
2003 280
6.5 US medical device companies - overseas revenue
mix 2003 281
6.6 Selected non-US medical device companies 281
6.7 Sources and consumption of medical products, US
and OUS, for 2003 283
6.8 Implant and usage rates per million population 284
6.9 Stent margin analysis comparing bare-metal with
drug-eluting 289
6.10 Direct sales personnel for selected product segments and
geographies 289
6.11 Marketing expenses for selected manufacturers in 2003 293
6.12 Operating expenses - averages and selected companies, 2003 294
6.13 Price to earnings ratios - comparisons between
Pharmaceuticals and medical products companies 296
6.14 Implantable defibrillator - Medtronic's models PCD
through Entrust 299
6.15 ICD ROM sizes 299
6.16 The number of acquisitions and their value 311
6.17 Concentration ratios - a consolidating industry 312
6.18 Medical products initial public offerings 314
7.1 Growth in healthcare IT spending 323
7.2 Moore's Law: transistors per microprocessor 325
7.3 Top healthcare software application providers 328
7.4 The emerging healthcare safety net 337
7.5 Consumer-directed health plans: a primer 341 |
| adam_txt |
Contents
List of figures page xi
List of contributors xvi
Preface xix
Acknowledgments xxi
1 The business of healthcare innovation in the Wharton
School curriculum 1
Lawton R. Bums
Part I The life sciences
2 The pharmaceutical sector 27
Jon Northrup
3 The biotechnology sector - therapeutics 103
Cary G. Pfeffer
4 Biotechnology business and revenue models: the dynamic of
technological evolution and capital market ingenuity 190
Stephen M. Sammut
5 Mergers, acquisitions, and the advantages of scale in the
pharmaceutical sector 223
Lawton R. Burns, Sean Nicholson, and John Evans
Part II Devices and information technologies
6 The medical device sector 271
Kurt Kruger
7 The healthcare information technology sector 322
Jeff C. Goldsmith
8 Healthcare innovation across sectors: convergences and divergences 348
Lawton R. Burns and Stephen M. Sammut
Index 365
Figures
1.1 The US healthcare value chain page 2
1.2 Technology and intensity of service as share of
annual percentage increase in US personal health
expenditures, 1961-1998 3
1.3 Composition of hospital expenses 11
1.4 Composition of hospital supply costs 12
1.5 Spending by category, 1980-2010 12
1.6 US healthcare manufacturing firms: revenues and rank
in Fortune 500 14
2.1 2003: heavily about the USA 29
2.2 Growth of key markets 30
2.3 Top worldwide countries (except USA) over \$4 billion
country sales 31
2.4 Sales of top companies, 2003 31
2.5 Twelve largest pharmaceutical companies grow to 2007,
slow to 2010 32
2.6 Therapeutic area growth, 2002-2010 33
2.7 Drug development attrition rate 35
2.8 Individual healthcare status 44
2.9 USA population over 65 years of age 46
2.10 Age profile in major markets, 2010: Brazil, Japan, US 47
2.11 Worldwide prescription consumers - 2010 48
2.12 Worldwide disease potential 52
2.13 Top twenty future diseases in 2010 52
2.14 Three dimensions of pharmaceutical strategy 53
2.15 The value chain 54
2.16 Varying scope of pharmaceutical business models 54
2.17 Stages in the discovery research process 56
2.18 The investment inflection point: addressing early attrition 60
2.19 Stages in the development process 60
2.20 Pharmaceutical business model - long cycle time and
high risk 61
2.21 Personalized medicine: genaissance example 63
2.22 Drug development cost 68
2.23 The innovation challenge 68
2.24 Technology applied to drug development 69
2.25 Key innovation levers are moving in the wrong direction 71
2.26 Drug candidate attrition: pull risk forward 71
2.27 Fast fails: comparison of two companies (early decision
and traditional development) 72
2.28 Pharmaceutical supply chain 74
2.29 Top 5,000 molecules by 2001 revenue 82
2.30 Blockbuster revenue correlates to shareholder returns 82
2.31 Increasing rewards from new launch standards 83
2.32 Spending begins early and aggressively 84
2.33 Total pharmaceutical promotional spend 84
2.34 US sales representatives "arms race" 85
2.35 E-detailing 88
2.36 Cycle times 90
2.37 Lilly's product archetypes 91
2.38 Goal - strong, steady innovation matched to
franchise engines 92
2.39 Pharmaceutical deals between 2002 and 2004 94
2.40 Alliance life cycle - breakdowns are normal 95
2.41 Key element of successful alliance management 96
2.42 It is not the number of shots on goal - data from 2000
NHL season 100
3.1 Discoveries driving the biotechnology industry 106
3.2 The biotechnology industry - year of company founding 108
3.3 Recent stock market performance 109
3.4 US biotechnology companies versus Merck and Pfizer 110
3.5 US biotechnology revenues 111
3.6 Selected biotechnology-derived drugs 112
3.7 Therapeutic monoclonal antibody products approved
in the US 117
3.8 Selected genomics companies 118
3.9 Selected proteomics companies 119
3.10 Selected systems biology companies 123
3.11 Technology platform companies 125
3.12 Selected Millennium pharmaceutical alliances 127
3.13 Selected Millennium acquisitions 128
3.14 Venture funding trends for NRDO companies versus
R D companies 130
3.15 NRDO versus R D company financings
(public and private) 130
3.16 IPOs versus venture capital funding 132
3.17 Financing alternatives 134
3.18 Biotech financing trends, 1996-2003 137
3.19 Biotech financings 1996 and 2003 138
3.20 Comparison of pharmaceutical and biotechnology
companies 140
3.21 What makes alliances work 142
3.22 Licensing deals by phase, 1998-2003 144
3.23 Selected early partial acquisitions in biotechnology 144
3.24 Value of prescription drugs coming off-patent 146
3.25 Selected M A transactions involving biotechnology
companies 149
3.26 Comparing the domestic biotech industry with the
rest of the world 154
3.27 Biotechnology products in development across Europe 155
3.28 UK biotechnology financing 156
3.29 Aggregate market capitalization of biotechnology
companies across Europe 157
3.30 Number of companies by European country 158
3.31 Canadian biotechnology: sources of funding 159
3.32 Number of Asian biotechnology companies
(public and private) by country 161
3.33 Top industries for Japanese venture capital investment 162
3.34 Selected biotechnology products in Japan in 2003 162
3.35 Funding sources for Australian biotechnology firms,
2001-2002 166
3.36 Selected challenges of commercializing drugs in
foreign markets 167
3.37 Federal biotechnology regulatory framework 168
3.38 FDA biologies approval times, 2001-2003 169
3.39 Trend of FDA biologies approval times 170
3.40 New product approvals (NMEs), 1996-2003 170
3.41 Selected top biopharmaceuticals and their biogeneric status 174
3.42 Orphan drug approvals 175
3.43 The pharmaceutical innovation gap 182
4.1 Innovation gap in pharmaceutical discovery and
development 196
4.2 Proteomics toolbox technologies 198
4.3 The "omics" development chain 199
4.4 Specialty participants in the proteomics continuum 201
4.5 Biotechnology industry characteristics in 2004 211
4.6 Capitalization trends in the US life sciences industry 212
4.7 Representation of the dynamics of biotechnology
strategies and structures and their revenue models 215
5.1 Number of "transforming" biotechnology and
pharmaceutical M A transactions 227
5.2 Merger history of top companies, 1979-2004 228
5.3 Alliances with biotechnology firms 230
5.4 Top rationales for recent pharmaceutical merger 250
5.5 An integrating industry 255
6.1 Medical device industry 272
6.2 Medical devices markets - major categories 2003 277
6.3 Cardiovascular product detail - 2003 revenue 278
6.4 A selection of large US medical device companies,
2003 280
6.5 US medical device companies - overseas revenue
mix 2003 281
6.6 Selected non-US medical device companies 281
6.7 Sources and consumption of medical products, US
and OUS, for 2003 283
6.8 Implant and usage rates per million population 284
6.9 Stent margin analysis comparing bare-metal with
drug-eluting 289
6.10 Direct sales personnel for selected product segments and
geographies 289
6.11 Marketing expenses for selected manufacturers in 2003 293
6.12 Operating expenses - averages and selected companies, 2003 294
6.13 Price to earnings ratios - comparisons between
Pharmaceuticals and medical products companies 296
6.14 Implantable defibrillator - Medtronic's models PCD
through Entrust 299
6.15 ICD ROM sizes 299
6.16 The number of acquisitions and their value 311
6.17 Concentration ratios - a consolidating industry 312
6.18 Medical products initial public offerings 314
7.1 Growth in healthcare IT spending 323
7.2 Moore's Law: transistors per microprocessor 325
7.3 Top healthcare software application providers 328
7.4 The emerging healthcare safety net 337
7.5 Consumer-directed health plans: a primer 341 |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| author | Madura, Jeff |
| author_facet | Madura, Jeff |
| author_role | aut |
| author_sort | Madura, Jeff |
| author_variant | j m jm |
| building | Verbundindex |
| bvnumber | BV020839694 |
| classification_rvk | QK 640 |
| ctrlnum | (OCoLC)254145015 (DE-599)BVBBV020839694 |
| dewey-full | 658.1599 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 658 - General management |
| dewey-raw | 658.1599 |
| dewey-search | 658.1599 |
| dewey-sort | 3658.1599 |
| dewey-tens | 650 - Management and auxiliary services |
| discipline | Wirtschaftswissenschaften |
| discipline_str_mv | Wirtschaftswissenschaften |
| edition | 8. ed., internat. student ed. |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a2200000 c 4500</leader><controlfield tag="001">BV020839694</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20080318</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">051020s2006 d||| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0324323824</subfield><subfield code="9">0-324-32382-4</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)254145015</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV020839694</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-1049</subfield><subfield code="a">DE-1051</subfield><subfield code="a">DE-858</subfield><subfield code="a">DE-83</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">658.1599</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">QK 640</subfield><subfield code="0">(DE-625)141673:</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Madura, Jeff</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">International corporate finance</subfield><subfield code="c">Jeff Madura</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">8. ed., internat. student ed.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Mason, Ohio</subfield><subfield code="b">Thomson South-Western</subfield><subfield code="c">2006</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XXIII, 707 S.</subfield><subfield code="b">graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Bis 7. Aufl. u.d.T.: Madura, Jeff: International financial management</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Multinationales Unternehmen / Betriebliche Finanzwirtschaft / Währungsmanagement / Welt</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Multinationales Unternehmen</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Foreign exchange</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Foreign exchange</subfield><subfield code="v">Problems, exercises, etc</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">International business enterprises</subfield><subfield code="x">Finance</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">International business enterprises</subfield><subfield code="x">Finance</subfield><subfield code="v">Problems, exercises, etc</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">International finance</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">International finance</subfield><subfield code="v">Problems, exercises, etc</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Internationaler Kreditmarkt</subfield><subfield code="0">(DE-588)4120506-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Finanzmanagement</subfield><subfield code="0">(DE-588)4139075-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Finanzmanagement</subfield><subfield code="0">(DE-588)4139075-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Internationaler Kreditmarkt</subfield><subfield code="0">(DE-588)4120506-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=014161594&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield></record></collection> |
| id | DE-604.BV020839694 |
| illustrated | Illustrated |
| index_date | 2024-07-02T13:16:04Z |
| indexdate | 2024-07-20T04:57:54Z |
| institution | BVB |
| isbn | 0324323824 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-014161594 |
| oclc_num | 254145015 |
| open_access_boolean | |
| owner | DE-1049 DE-1051 DE-858 DE-83 |
| owner_facet | DE-1049 DE-1051 DE-858 DE-83 |
| physical | XXIII, 707 S. graph. Darst. |
| publishDate | 2006 |
| publishDateSearch | 2006 |
| publishDateSort | 2006 |
| publisher | Thomson South-Western |
| record_format | marc |
| spelling | Madura, Jeff Verfasser aut International corporate finance Jeff Madura 8. ed., internat. student ed. Mason, Ohio Thomson South-Western 2006 XXIII, 707 S. graph. Darst. txt rdacontent n rdamedia nc rdacarrier Bis 7. Aufl. u.d.T.: Madura, Jeff: International financial management Multinationales Unternehmen / Betriebliche Finanzwirtschaft / Währungsmanagement / Welt Multinationales Unternehmen Foreign exchange Foreign exchange Problems, exercises, etc International business enterprises Finance International business enterprises Finance Problems, exercises, etc International finance International finance Problems, exercises, etc Internationaler Kreditmarkt (DE-588)4120506-6 gnd rswk-swf Finanzmanagement (DE-588)4139075-1 gnd rswk-swf Finanzmanagement (DE-588)4139075-1 s Internationaler Kreditmarkt (DE-588)4120506-6 s DE-604 HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=014161594&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Madura, Jeff International corporate finance Multinationales Unternehmen / Betriebliche Finanzwirtschaft / Währungsmanagement / Welt Multinationales Unternehmen Foreign exchange Foreign exchange Problems, exercises, etc International business enterprises Finance International business enterprises Finance Problems, exercises, etc International finance International finance Problems, exercises, etc Internationaler Kreditmarkt (DE-588)4120506-6 gnd Finanzmanagement (DE-588)4139075-1 gnd |
| subject_GND | (DE-588)4120506-6 (DE-588)4139075-1 |
| title | International corporate finance |
| title_auth | International corporate finance |
| title_exact_search | International corporate finance |
| title_exact_search_txtP | International corporate finance |
| title_full | International corporate finance Jeff Madura |
| title_fullStr | International corporate finance Jeff Madura |
| title_full_unstemmed | International corporate finance Jeff Madura |
| title_short | International corporate finance |
| title_sort | international corporate finance |
| topic | Multinationales Unternehmen / Betriebliche Finanzwirtschaft / Währungsmanagement / Welt Multinationales Unternehmen Foreign exchange Foreign exchange Problems, exercises, etc International business enterprises Finance International business enterprises Finance Problems, exercises, etc International finance International finance Problems, exercises, etc Internationaler Kreditmarkt (DE-588)4120506-6 gnd Finanzmanagement (DE-588)4139075-1 gnd |
| topic_facet | Multinationales Unternehmen / Betriebliche Finanzwirtschaft / Währungsmanagement / Welt Multinationales Unternehmen Foreign exchange Foreign exchange Problems, exercises, etc International business enterprises Finance International business enterprises Finance Problems, exercises, etc International finance International finance Problems, exercises, etc Internationaler Kreditmarkt Finanzmanagement |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=014161594&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT madurajeff internationalcorporatefinance |